MedTrace Logo

Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide, Rituximab +/- Nivolumab.

NCT05788081 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-08-20

No results posted yet for this study

Summary

First line treatment with combination rituximab and golcadomide with, or without nivolumab, in patients in previously untreated Follicular Lymphoma

Conditions

  • Follicular Lymphoma Stage II
  • Follicular Lymphoma Stage III
  • Follicular Lymphoma Stage IV

Interventions

DRUG

golcadomide

BMS-986369 is an orally administered Cereblon-modulating compound

DRUG

Nivolumab 10 MG/ML

Nivolumab is a fully humanised IgG4 blocking monoclonal antibody against PD-1.

DRUG

Rituximab

Rituximab is a chimeric anti-CD20 antibody containing human IgG lambda and kappa constant regions with murine variable regions

Sponsors & Collaborators

  • Austin Health

    collaborator OTHER_GOV

  • Grampians Health

    collaborator UNKNOWN

  • Fiona Stanley Hospital

    collaborator OTHER

  • Eastern Health

    collaborator OTHER

  • Barwon Health

    collaborator OTHER_GOV

  • Bristol-Myers Squibb

    collaborator INDUSTRY

  • Olivia Newton-John Cancer Research Institute

    lead OTHER

Principal Investigators

  • Eliza Hawkes, MBBS · Austin Health

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-31
Primary Completion
2027-01-01
Completion
2027-06-01

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05788081 on ClinicalTrials.gov